Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
The T. Rowe Price Health Sciences Fund falls into Morningstar’s health category. Funds in this category generally buy stocks in the medical and health care industries. According to T. Rowe Price's ...
Stifel lowered the firm’s price target on Exact Sciences (EXAS) to $67 from $82 and keeps a Buy rating on the shares. Below-consensus Q3 results and a reduced Q4 outlook stem from multiple issues – ...
) has been revised to $84.57 / share. This is an increase of 18.76% from the prior estimate of $71.21 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...
) has been revised to $5.10 / share. This is an increase of 150.00% from the prior estimate of $2.04 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from $8, while maintaining a “Buy” rating, following updated clinical data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results